Free Trial

Royalty Pharma (RPRX) Earnings Date, Estimates & Call Transcripts

Royalty Pharma logo
$24.92 +0.64 (+2.64%)
(As of 12/20/2024 05:51 PM ET)
Get Royalty Pharma Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Royalty Pharma and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

RPRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RPRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Royalty Pharma Analyst EPS Estimates

Current Year EPS Consensus Estimate:$4.10 EPS
Next Year EPS Consensus Estimate: $4.31 EPS

Royalty Pharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/8/2024Q2 2024$0.95$0.96+$0.01$1.75$600.83M$537.00M
5/9/2024Q1 2024$0.96$0.98+$0.02$1.95$671.45M$568.00M
2/15/2024Q4 2023$1.03$1.15+$0.12$1.47$702.90M$736.00M
11/8/2023Q3 2023$0.81$0.79 -$0.02$1.46$640.96M$637.00M
8/8/2023Q2 2023$0.83$0.85+$0.02$1.32$538.52M$545.00M
5/9/2023Q1 2023$1.32$1.60+$0.28$2.64$914.72M$1.13B
2/15/2023Q4 2022$1.56$1.56-$3.87$1.06B$1.06B

Royalty Pharma Earnings - Frequently Asked Questions

Royalty Pharma (NASDAQ:RPRX) has a recorded annual revenue of $2.27 billion.

Royalty Pharma (NASDAQ:RPRX) has a recorded net income of $1.13 billion. RPRX has generated $1.93 earnings per share over the last four quarters.

Royalty Pharma (NASDAQ:RPRX) has a trailing price-to-earnings ratio of 12.91 and a forward price-to-earnings ratio of 6.08. The price/earnings-to-growth ratio is 4.36.

Royalty Pharma's earnings are expected to grow from $4.10 per share to $4.31 per share in the next year, which is a 5.12% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:RPRX) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners